



## RESEARCH ARTICLE

### Detection of Plasmid-Mediated Quinolone Resistance Genes in Swine Clinical Isolates of *Escherichia coli*

Wenxin Lyu<sup>1,2§</sup>, Yuefei Yang<sup>1,2§</sup>, Junzhao Li<sup>1,2</sup> and Yanhong Wang<sup>\*1,2,3</sup>

<sup>1</sup>College of Veterinary Medicine, Yangzhou University, Yangzhou 225009, China; <sup>2</sup>Jiangsu Co-innovation Center for Prevention and Control of Important Animal Infectious Diseases and Zoonoses, Yangzhou, 225009, China; <sup>3</sup>Jiangsu Key Laboratory of Zoonosis, Yangzhou 225009, China

\*Corresponding author: wyh7405@163.com

#### ARTICLE HISTORY (17-259)

Received: July 24, 2017  
Revised: October 03, 2017  
Accepted: October 28, 2017  
Published online: November 21, 2017

#### Key words:

*Escherichia coli*  
PMQR  
Resistance

#### ABSTRACT

The drug resistance was investigated in swine clinical isolates of *Escherichia coli* in East China, and the prevalence of plasmid-mediated quinolone resistance (PMQR) genes was detected by PCR and sequencing. Among 53 clinical *E. coli* isolates, 47 (88.7%) isolates exhibited resistance to one or more antimicrobial agents, with the greatest resistance in norfloxacin (69.8%) and ciprofloxacin (67.9%) and the lowest resistance in amikacin (17.0%). In total, *aac(6')-Ib*, *qnr* and *qepA* were detected in 10 (18.9%), 10 (18.9%) and 1 (1.9%) of 53 *E. coli* isolates. The 10 *qnr*-positive isolates include 5 for *qnrB* and 5 for *qnrS*, whereas no *qnrA* and *qnrD* were detected. Noteworthy, 90% (9/10) *aac(6')-Ib*-positive isolates were the *cr* variant allele. The fact that, none resistance gene was detected in some isolates with severe drug resistance, suggests that there may be other potential genes or mechanisms mediating it.

©2017 PVJ. All rights reserved

**To Cite This Article:** Lyu W, Yang Y, Li J and Wang Y, 2018. Detection of plasmid-mediated quinolone resistance genes in swine clinical isolates of *Escherichia coli*. Pak Vet J, 38(1): 86-90.

<http://dx.doi.org/10.29261/pakvetj/2018.017>

#### INTRODUCTION

*Escherichia coli* is the most common pathogen, which can cause infectious diseases such as enteritis or septicemia in both humans and animals (Croxen *et al.*, 2013), and the antimicrobial resistance of *E. coli* is on the rise in recent decades, which complicated the treatment of serious infections and even may lead to death (Jim, 2016). According to the statistics, there are over 0.7 million people dying from the infection of drug-resistant bacteria all over the world (Jim, 2016). *E. coli* is one of the bacteria most often resistant to drug and by 2050, over 3 million people will die from infection of *E. coli* if measures are not taken to reduce it (Jim, 2016). The mechanisms of plasmid-mediated quinolone resistance (PMQR) include 1) *qnr* proteins (*qnrA*, *qnrS*, *qnrB*, *qnrC*, *qnrD*), which belong to the large pentapeptide repeat family 2) the *aac(6')-Ib-cr*, which is a bifunctional aminoglycoside acetyltransferase variant that can acetylate fluoroquinolones such as ciprofloxacin and norfloxacin, and 3) the efflux pump, *qepA* and *oqxAB*, which has been recently discovered to reduce

susceptibility to hydrophilic fluoroquinolones (Jacoby *et al.*, 2014; Hooper and Jacoby, 2015). The plasmid-mediated mechanisms only provide low-level resistance to quinolones, but it is reported that PMQR genes can facilitate the mutant selection of high-level resistance to quinolone (Jacoby *et al.*, 2014).

The prevalence of PMQR genes has been widely reported in the world in human's clinical infectious bacteria, like *Escherichia coli* and *Klebsiella* spp. (Wang *et al.*, 2004; Karah *et al.*, 2010). However, few articles have reported the PMQR genes in veterinary clinical *E. coli* isolates. Because of the great use of aminoglycoside and fluoroquinolone in treating swine infectious diseases, the emergence and spread of resistant strains is becoming a serious problem. The objectives of this study were: 1) to investigate the relatedness between the drug resistance and prevalence of PMQR genes; 2) to investigate the aberration rate of *aac(6')-Ib* and whether it is associated with the resistance to fluoroquinolones.

#### MATERIALS AND METHODS

**Bacteria strains:** The *Escherichia coli* used in this study was isolated from diseased or dead swines from East

§These authors contributed equally to this work.

China (Shanghai, Jiangsu Province, Anhui Province and Shandong Province) between March 2015 to April 2017. The clinical samples of liver, duodenum, kidney, spleen, lung and heart were seeded in blood agar and the single colony was then seeded in Mac-Conkey agar for purification. For further identification, the colonies turning pink were smeared for Gram staining and observed under the oil-immersion microscope and all *E. coli*-like colonies were identified by conventional biochemical analyses.

**Detection of PMQR genes and sequencing:** The presence of PMQR genes including *qnrA*, *qnrS*, *qnrB*, *qnrD*, *aac(6')-Ib* and *qepA* was investigated by PCR amplification and gel electrophoresis. All primers were shown in Table 1. The DNA templates were prepared by boiling lysis. The PCR conditions for *qnrA*, *qnrB*, *qnrS* and *aac(6')-Ib* were as follows: initial step of 94°C for 5 min, 30 cycles consisting of 94°C for 1 min, 48°C for 45 sec for *qnrA* as well as 52°C for 45 sec for *qnrB*, *qnrS* and *aac(6')-Ib*, and 72°C for 1 min, and a final extension step of 72°C for 8 min. The detection of *qnrD* and *qepA* was conducted as previously described (Yamane *et al.*, 2008; Cavaco *et al.*, 2009). All positives were further confirmed by sequencing and compared with GenBank sequences using BLAST algorithms (www.ncbi.nlm.nih.gov).

**Susceptibility testing:** According to the judgment standard of the Clinical and Laboratory Standards Institutes (CLSI, 2009), the susceptibility testing was determined by Kirby-Bauer Disk Diffusion. The types of antimicrobial agents and the breakpoints were shown in Table 2.

**Table 1:** Primers used in this study

Gene	Primer Sequence (5' -3')	Size (bp)	Reference
<i>aac(6')-Ib</i>	TTGCGATGCTCTATGAGTGGCTA	482	Park <i>et al.</i> , 2006
	CTCGAATGCCTGGCGTGTTT		
<i>qnrA</i>	TCAGCAAGAGGATTTCTCA	627	Wang <i>et al.</i> , 2004
	GGCAGCACTATTACTCCCA		
<i>qnrB</i>	GATCGTGAAAGCCAGAAAAGG	469	Gay <i>et al.</i> , 2006
	ACGATGCCTGGTAGTTGTCC		
<i>qnrS</i>	ACGACATTCGTCAACTGCAA	417	Gay <i>et al.</i> , 2006
	TAAATTGGCACCCCTGTAGGC		
<i>qnrD</i>	CGAGATCAATTTACGGGGAATA	533	Cavaco <i>et al.</i> , 2009
	AACAAGCTGAAGCGCCTG		
<i>qepA</i>	GCAGGTCCAGCAGCGGGTAG	199	Yamane <i>et al.</i> , 2008
	CTTCTGCCCGAGTATCGTG		

**Table 2:** Judgment standard of drug resistance

Drug class	Antimicrobial drug <sup>a</sup>	Drug content/ $\mu$ g	Breakpoints		
			Resistant	Intermediate	Susceptible
Fluoroquinolones	CIP	5	$\leq 15$	16-20	$\geq 21$
	NOR	10	$\leq 12$	13-16	$\geq 17$
	LVX	5	$\leq 13$	14-16	$\geq 17$
Aminoglycosides	GEN	10	$\leq 12$	13-14	$\geq 15$
	TOB	10	$\leq 12$	13-14	$\geq 15$
	AMK	30	$\leq 14$	15-16	$\geq 17$
$\beta$ -lactams	MEZ	75	$\leq 17$	18-20	$\geq 21$
	CRO	30	$\leq 13$	14-20	$\geq 21$

<sup>a</sup>CIP, ciprofloxacin; NOR, norfloxacin; LVX, levofloxacin; GEN, gentamicin; TOB, tobramycin; AMK, amikacin; MEZ, mezlocillin; CRO, ceftriaxone.

## RESULTS

**Isolation and identification of *E. coli*:** Totally, 53 *E. coli* strains were isolated from diseased organs or tissues (22 from duodenum, 9 from liver, 3 from lung, 7 from kidney,

6 from spleen and 6 from heart or hydropericardium) of sick and dead pigs in East China, which were sent to Animal Hospital of Yangzhou University from March 2015 to April 2017. All 53 strains grew well with smooth, moist and round colonies and turned pink on Mac-Conkey agar.

The strains were red and dispersedly distributed under the microscopy, which were Gram-negative bacteria. As for the conventional biochemical analyses, all strains can ferment glucose, lactose, maltose, mannose and sucrose. The IMViC tests showed that the strains were positive to indole test and methyl red test and were negative to VP test and citrate test. All these outcomes correspond to the biochemical characteristics of *E. coli*.

**Prevalence of PMQR genes:** Among the detected PMQR genes, there were 10 (18.9%, 10/53) strains being positive for *qnr* genes, with 5 for *qnrB* and 5 for *qnrS* respectively. And only 1 strain carried the efflux pump gene *qepA*. In addition, no *qnrA* and *qnrD* was detected.


As for aminoglycoside acetyltransferase, 10 (18.9%, 10/53) strains were detected carrying the *aac(6')-Ib*. 1 strain carried both *aac(6')-Ib-cr* and *qnrB*. The 10 *aac(6')-Ib*-positive strains were used to conduct phylogenetic analysis. Noteworthy, nine strains were phylogenetically related to previously published strain of *Escherichia coli* WJ1 (GenBank No: KY924928) with the aberrant gene of *aac(6')-Ib-cr*, which can also acetylate the fluoroquinolones, and only one strain were related to previously published strain of *Enterobacter cloacae* CY01 (GenBank No: NC025003) with the normal gene of *aac(6')-Ib* (Fig. 1). As shown in Fig. 2, all the *-cr* variant has two substitutions: Trp128Arg and Asp205Tyr, compared with the other *aac(6')-Ib* and the standard CY01.

All the sequenced genes have been submitted to the GenBank (*aac(6')-Ib*: No.MF999208-217; *qnrB*: No. MF999218-219; *qnrS*: No.MF999210-211; *qepA*:MF999222).

**Antimicrobial drug resistance:** 88.7% (47/53) strains showed resistance to one or more antimicrobial agents, among which there are 10 strains resistant to three kinds of antimicrobials. As shown in Table 3, the most serious resistance is norfloxacin and ciprofloxacin, with the resistance rate up to 69.8% and 67.9%. The resistance rate of amikacin is the lowest, which is only 17.0%.

**Genotype-phenotype correlation:** The genotype-phenotype correlation is discussed by the agreement rate, which represents the proportion of gene-carrying isolates among the drug-resistant isolates. The genotype-phenotype agreement rate of PMQR genes to aminoglycosides or fluoroquinolones has been shown in Table 4. The gene *aac(6')-Ib* has the highest rate to gentamicin and the lowest rate to amikacin. With regard to fluoroquinolones, the *-cr* variant has the highest rate to ciprofloxacin and norfloxacin, which is 25.0% and 24.3% respectively. The agreement rates of *qnrB*, *qnrS* and *qepA* are all less than 10%.

As to *9-cr* variant-positive isolates, all of them are resistant to ciprofloxacin and norfloxacin, with the proportion reaching to 100% (Table 5). What's more, in 19 PMQR-positive strains, 11 (57.9%) strains are also resistant to  $\beta$ -lactams at the same time.



**Fig. 1:** Phylogenetic analysis of *aac(6)-Ib*-positive strains based on Neighbor-joining method with 1000 bootstrap replicas using Mega 4.0. DNA sequences of *Escherichia coli* WJ1 (GenBank No: KY924928) and *Enterobacter cloacae* CY01 (GenBank No: NC025003) were downloaded from the NCBI Webpage ([www.ncbi.nlm.nih.gov](http://www.ncbi.nlm.nih.gov)). Numbers at the node are bootstrap values and the bar represents nucleotide changes.

**Table 3:** Antimicrobial resistance of *E. coli*.

Antimicrobial drug	Resistant		Intermediate		susceptible	
	No. of isolates	Ratio	No. of isolates	Ratio	No. of isolates	Ratio
CIP	36	67.9	4	7.5	13	24.5
NOR	37	69.8	3	5.7	13	24.5
LVX	32	60.4	7	13.2	14	26.4
GEN	25	47.2	8	15.1	20	37.7
TOB	18	34.0	5	9.4	30	56.6
AMK	9	17.0	1	1.9	43	81.1
MEZ	30	56.6	9	17.0	14	26.4
CRO	11	20.8	10	18.9	32	60.4

## DISCUSSION

In recent years, the drug resistance is always on the rise in animals or food, which has killed many lives of animals and also threatens the human health. From 2008 to 2015, the antimicrobial resistance was severe with high prevalence of MDR *E. coli* in swine and chicken in China (Zhang *et al.*, 2017). In meat products, Jiang *et al.* (2014) have found over 90% resistance and demonstrated the prevalence of resistant genes, which may transfer to humans via the food chain. In this study, the 53 isolates of *E. coli* were all isolated from East China from March 2015 to April 2017, hence, the detection results of resistance genes can reflect the current situation in swine and help us to take effective measures.

According to the drug sensitivity results, the drug resistance of *E. coli* in swine in this area is very serious, with the drug resistance rate up to 88.7% and MDR (multidrug resistance) rate up to 18.9%. And proportion of the potential MDR strains may be much higher than this data if we add more drug categories into the test. Generally, the resistance to fluoroquinolones is much more severe than the resistance to aminoglycosides and  $\beta$ -lactams, which may relate to the clinical medication. Corresponding to Jiang *et al.* (2014) research results of *E. coli*, amikacin has the lowest rate of 17.0%, and this

suggests that amikacin can be used as the first choice to treat for serious infection of *E. coli* in the future.

The prevalence of PMQR genes in *E. coli* has been reported in many hospitals or laboratories all over the world (Strahilevitz *et al.*, 2007; Karah *et al.*, 2010), but only few studies investigated the *E. coli* isolated from swine.

According to the phylogenetic analysis (Fig. 1), the *aac(6)-Ib* has a high proportion of aberrance, which is consistent to many other studies (Park *et al.*, 2006; Karah *et al.*, 2010; Jiang *et al.*, 2014). The amino acid substitutions (Trp128Arg and Asp205Tyr) are analogous to Trp102Arg and Asp179Tyr (Jacoby *et al.*, 2014), and this 26 amino acid larger *aac(6)-Ib-cr* has also been reported (de Toro *et al.*, 2013). The recent studies showed that the *aac(6)-Ib-cr* can mediate the resistance to ciprofloxacin and norfloxacin (Jacoby *et al.*, 2014). Although the agreement rates of these two agents are only 25.0% and 24.3%, the resistance rate reaches 100% in the 9 *-cr* variant-positive strains, which suggests the high concordance in the function to the two agents.

As an aminoglycoside acetyltransferase, *aac(6)-Ib* mainly modifies gentamicin and amikacin (Jacoby *et al.*, 2014), which does not agree with the observed low prevalence of amikacin resistance. Similar phenomenon has been reported in many other articles (Lindemann *et al.*, 2012; Haldorsen *et al.*, 2014), which suggests that the current breakpoint of amikacin cannot reflect the prevalence of aminoglycoside acetyltransferase precisely. Study also shows that there are differences in *aac(6)-I*-caused resistance affected by host bacterium (Haldorsen *et al.*, 2014). In addition, it has been suggested that the activity towards amikacin can be influenced by the mutations in *aac(6)-Ib* (Shmara *et al.*, 2001).

In many studies, only 1 or 2 *E. coli* isolates from human beings have been detected to carry *qnrA*, and most of them were resistant to ciprofloxacin or producing extended-spectrum  $\beta$ -lactamases (ESBLs) (Wang *et al.*, 2004; Karah *et al.*, 2010). Further, there is study showing that the detection rate of *qnrA* was 0% in animals in Guangzhou, China (Yue *et al.*, 2008). Our study also has not found *qnrA*, so the prevalence of *qnrA* was generally low in both human and veterinary clinical isolates. *QnrD* was first defined by Cavaco *et al.* (2009) but the prevalence trend of *qnrD* in *E. coli* was not clear so far. Compared with *qnrA* and *qnrD*, *qnrB* and *qnrS* is somewhat more common, which corresponds to studies in recent years (Yue *et al.*, 2008; Karah *et al.*, 2010). The detection of *qnr* genes has been increasing in studies of the past decade, but it is still less than 10% in unselected clinical samples. What's more, in comparison with *E. cloacae* and *K. pneumoniae*, the prevalence of *qnr* in *E. coli* is the least (Kim *et al.*, 2013; Jacoby *et al.*, 2014).

In this study, only 1 (1.9%) of 53 strains was *qepA*-positive. Although *qepA* gene has been detected in Japan and Korea many times (Yamane *et al.*, 2008; Kim *et al.*, 2009), the prevalence of it was less than 2%. The *qepA* was first found in multidrug resistant *E. coli*, carrying several other drug resistant genes (Cantón, 2009). The only 1 *qepA*-positive strain in this study also carries *aac(6)-Ib*, which explains the cause of multidrug resistance of this strain.

#E2	MSLKPGPKRI	AESTGQPDQR	QRDNKKTGPN	TDKLGITKYS	IVTNSTDSVT	LRLMTEHDLA	MLYEWLNRSH	IVEWVGEEA
#E3	.....	.....	.....	.....	.....	.....	.....	.....
#E5	.....	.....	.....	.....	.....	.....	.....	.....
#E20	.....	.....	.....	.....	.....	.....	.....	.....
#E26	.....	.....	.....	.....	.....	.....	.....	.....
#E29	.....	.....	.....	.....	.....	.....	.....	.....
#E30	.....	.....	.....	.....	.....	.....	.....	.....
#E31	.....	.....	.....	.....	.....	.....	.....	.....
#E32	.....	.....	.....	.....	.....	.....	.....	.....
#E44	.....	.....	.....	.....	.....	.....	.....	.....
#NC025003	.....	.....	.....	.....	.....	.....	.....	.....
#E2	RPTLADVQEQ	YLPSVLAQES	VTPYIAMLNG	EPIGYAQSIV	ALGSGDGRWE	EETDPGVRGI	DQLLANASQL	GKGLGTLKLR
#E3	.....	.....	.....	.....	.....	.....	.....	.....
#E5	.....	.....	.....	.....	.....	.....	.....	.....
#E20	.....	.....	.....	.....	.....	.....	.....	.....
#E26	.....	.....	.....	.....	.....	.....	.....	.....
#E29	.....	.....	.....	.....	.....	.....	.....	.....
#E30	.....	.....	.....	.....	.....	.....	.....	.....
#E31	.....	.....	.....	.....	.....	.....	.....	.....
#E32	.....	.....	.....	.....	.....	.....	.....	.....
#E44	.....	.....	.....	.....	.....	.....	.....	.....
#NC025003	.....	.....	.....	.....	.....	.....	.....	.....
#E2	ALVELLFNDP	EVTKIQTDP	PSNLRAIRCY	EKAGFERQGT	VTTPIYGPVAVY	MVQTR		
#E3	.....	.....	.....	.....	.....	.....		
#E5	.....	.....	.....	.....	.....	.....		
#E20	.....	.....	.....	.....	.....	.....		
#E26	.....	.....	.....	.....	.....	.....		
#E29	.....	.....	.....	.....	.....	.....		
#E30	.....	.....	.....	.....	.....	.....		
#E31	.....	.....	.....	.....	.....	.....		
#E32	.....	.....	.....	.....	.....	.....		
#E44	.....	.....	.....	.....	.....	.....		
#NC025003	.....	.....	.....	.....	.....	.....		

**Fig. 2:** The DNA sequences of 10 detected *aac(6′)-Ib*-positive strains and *Enterobacter cloacae* CY01 have been translated and aligned by ClustalW using MEGA 4.0. The amino acid of location 128 and 205 has been substituted.

**Table 4:** Genotype-phenotype agreement rate<sup>a</sup>

Antimicrobial drug	<i>aac(6′)-Ib</i>	Antimicrobial drug	<i>aac(6′)-Ib-cr</i>	<i>qnrB</i>	<i>qnrS</i>	<i>qepA</i>
GEN	28.0(7/25)	CIP	25.0(9/36)	8.3(3/36)	5.6(2/36)	2.8(1/36)
TOB	44.4(8/18)	NOR	24.3(9/27)	5.4(2/37)	5.4(2/37)	2.7(1/37)
AMK	22.2(2/9)	LVX	15.6(5/32)	6.3(2/32)	6.3(2/32)	3.1(1/32)

<sup>a</sup>agreement rate=No. of isolates carrying genes/No. of resistant isolates×100%.

**Table 5:** Distribution of PMQR genes among *E. coli* clinical isolates

Sample ID	<i>Aac(6′)-Ib</i>	<i>qnr</i>	<i>qepA</i>	Fluoroquinolones phenotype	Aminoglycosides phenotype	β-lactams phenotype
E2	+, -cr <sup>a</sup>	—	—	CIP, NOR, LVX	TOB	
E3	+, -cr	—	—	CIP, NOR, LVX	GEN, TOB	
E5	+, -cr	<i>qnrB</i>	—	CIP, NOR	GEN, TOB	
E9	—	<i>qnrB</i>	—			MEZ
E12	—	<i>qnrS</i>	—	CIP, NOR, LVX	GEN	MEZ
E15	—	<i>qnrB</i>	—	CIP, NOR, LVX		MEZ, CRO
E16	—	<i>qnrS</i>	—			MEZ
E17	—	<i>qnrS</i>	—	CIP, NOR, LVX	GEN	MEZ
E20	+, -cr	—	—	CIP, NOR	TOB	
E26	+, -cr	—	—	CIP, NOR, LVX	GEN, TOB	MEZ
E29	+, -cr	—	—	CIP, NOR, LVX	GEN	MEZ
E30	+, -cr	—	—	CIP, NOR, LVX	GEN, TOB, AK	MEZ
E31	+, -cr	—	—	CIP, NOR	TOB	
E32	+, -cr	—	—	CIP, NOR	GEN	MEZ
E37	—	<i>qnrS</i>	—			
E43	—	<i>qnrS</i>	—		TOB	MEZ
E44	+	—	+	CIP, NOR, LVX	GEN, TOB, AMK	MEZ, CRO
E45	—	<i>qnrB</i>	—	CIP, NOR, LVX		
E47	—	<i>qnrB</i>	—	CIP		

<sup>a</sup>-cr, cr variant.

In the 19 PMQR-positive strains, 57.9% (11/19) strains were also resistant to β-lactams, such as Mezlocillin and Ceftriaxone, suggesting that PMQR genes may be associated with the resistance to β-lactams (Table 5). There're studies proving that the prevalence of *aac(6′)-Ib-cr* and *qnr* among ESBL-producing strains was significantly higher than non-ESBL-producing strains

(Karah *et al.*, 2010; Briales *et al.*, 2012; Haldorsen *et al.*, 2014).

The prevalence of PMQR genes in this study is generally low, while the drug sensitivity results showed that the resistance to fluoroquinolones was the severest. This difference may be influenced by some other drug resistant mechanisms, like the mutations in DNA gyrase

and topoisomerase IV. These plasmid-mediated genes can only confer low-level resistance, but it is proved that PMQR genes can facilitate bacterium to acquire other resistant genes, which can lead to high-level resistance (Karah *et al.*, 2010; Jacoby *et al.*, 2014). Hence, more focus and research should be given to it in the future.

**Acknowledgements:** This work was supported in part by the Open Project Program of Jiangsu Key Laboratory of Zoonosis (No. R1708), A Project Funded by the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD) and Top-notch Academic Programs Project of Jiangsu Higher Education Institutions (TAPP, PPZY2015B158).

**Authors contribution:** Study design: WL and YW; Experimentation: WL, YY and JL; Article writing: WL, YY and YW; Data analysis: WL and YW.

## REFERENCES

- Briales A, Rodríguez-Martínez JM, Velasco C, *et al.*, 2012. Prevalence of plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in *Escherichia coli* and *Klebsiella pneumoniae* producing extended-spectrum  $\beta$ -lactamases in Spain. *Int J Antimicrob Agents* 39:431-4.
- Cantón R, 2009. Antibiotic resistance genes from the environment: a perspective through newly identified antibiotic resistance mechanisms in the clinical setting. *Clin Microbiol Infect* 15:20-5.
- Cavaco LM, Hasman H, Xia S, *et al.*, 2009. qnrD, a novel gene conferring transferable quinolone resistance in *Salmonella enterica* serovar kentucky and bovismorbificans strains of human origin. *Antimicrob Agents Chemother* 53:603-8.
- Croxen MA, Law RJ, Scholz R, *et al.*, 2013. Recent advances in understanding enteric pathogenic *Escherichia coli*. *Clin Microbiol Rev* 26:822-80.
- de Toro M, Rodríguez I, Rojo-Bezares B, *et al.*, 2013. pMdTI, a small ColE1-like plasmid mobilizing a new variant of the aac(6')-Ib-cr gene in *Salmonella enterica* serovar Typhimurium. *J Antimicrob Chemother* 68:1277-80.
- Gay K, Robicsek A, Strahilevitz J, *et al.*, 2006. Plasmid-mediated quinolone resistance in non-typhi serotypes of *Salmonella enterica*. *Clin Infect Dis* 43:297-304.
- Haldorsen BC, Simonsen GS, Sundsfjord A, *et al.*, 2014. Increased prevalence of aminoglycoside resistance in clinical isolates of *Escherichia coli* and *Klebsiella* spp. in Norway is associated with the acquisition of AAC(3)-II and AAC(6')-Ib. *Diagn Microbiol Infect Dis* 78:66-9.
- Hooper DC and Jacoby GA, 2015. Mechanisms of drug resistance: quinolone resistance. *Ann N Y Acad Sci* 1354:12-31.
- Jacoby GA, Strahilevitz J and Hooper DC, 2014. Plasmid-mediated quinolone resistance. *Microbiol Spectr* 2:PLAS-0006-2013.
- Jiang X, Yu T, Wu N, *et al.*, 2014. Detection of qnr, aac(6')-Ib-cr and qepA genes in *Escherichia coli* isolated from cooked meat products in Henan, China. *Int J Food Microbiol* 187:22-5.
- Jim ON, 2016. Tackling drug-resistant infections globally: final report and recommendations. Review on Antimicrobial Resistance. London.
- Karah N, Poirel L, Bengtsson S, *et al.*, 2010. Plasmid-mediated quinolone resistance determinants qnr and aac(6')-Ib-cr in *Escherichia coli* and *Klebsiella* spp. from Norway and Sweden. *Diagn Microbiol Infect Dis* 66:425-31.
- Kim ES, Jeong JY, Choi SH, *et al.*, 2009. Plasmid-mediated fluoroquinolone efflux pump gene, qepA, in *Escherichia coli*, clinical isolates in Korea. *Diagn Microbiol Infect Dis* 65:335-8.
- Kim NH, Choi EH, Sung JY, *et al.*, 2013. Prevalence of plasmid-mediated quinolone resistance genes and ciprofloxacin resistance in pediatric bloodstream isolates of Enterobacteriaceae over a 9-year period. *Jpn J Infect Dis* 66:151-4.
- Lindemann PC, Risberg K, Wiker HG, *et al.*, 2012. Aminoglycoside resistance in clinical *Escherichia coli* and *Klebsiella pneumoniae* isolates from Western Norway. *Apmis* 120:495-502.
- Park CH, Robicsek A, Jacoby GA, *et al.*, 2006. Prevalence in the United States of aac(6')-Ib-cr encoding a ciprofloxacin-modifying enzyme. *Antimicrob Agents Chemother* 50:3953-5.
- Shmara A, Weinsattel N, Dery K, *et al.*, 2001. Systematic analysis of a conserved region of the aminoglycoside 6'-N-acetyltransferase type Ib. *Antimicrob Agents Chemother* 45:3287-92.
- Strahilevitz J, Engelstein D, Adler A, *et al.*, 2007. Changes in qnr prevalence and fluoroquinolone resistance in clinical isolates of *Klebsiella pneumoniae* and *Enterobacter* spp. collected from 1990 to 2005. *Antimicrob Agents Chemother* 51:3001-3.
- Wang M, Sahn D, Jacoby GA, *et al.*, 2004. Emerging plasmid-mediated quinolone resistance associated with the qnr gene in *Klebsiella pneumoniae* clinical isolates in the United States. *Antimicrob Agents Chemother* 48:1295-9.
- CLSI, 2009. Performance Standards for antimicrobial susceptibility testing: nineteenth informational supplement. Clinical and Laboratory Standards Institute.
- Yamane K, Wachino J, Suzuki S, *et al.*, 2008. Plasmid-mediated qepA gene among *Escherichia coli* clinical isolates from Japan. *Antimicrob Agents Chemother* 52:1564-6.
- Yue L, Jiang HX, Liao XP, *et al.*, 2008. Prevalence of plasmid-mediated quinolone resistance qnr, genes in poultry and swine clinical isolates of *Escherichia coli*. *Vet Microbiol* 132:414-20.
- Zhang P, Shen Z, Zhang C, *et al.*, 2017. Surveillance of antimicrobial resistance among *Escherichia coli* from chicken and swine, China, 2008-2015. *Vet Microbiol* 203:49-55.